Stocks slip on Wall Street over renewed concerns over virus


In this March 23, 2021 file photo, pedestrians walk past the New York Stock Exchange in New York's Financial District. Stocks are opening lower on Wall Street after the head of a major vaccine maker expressed concern about how effective current jabs will be against the new variant of the coronavirus. The S&P 500 gave back 0.6%, the Nasdaq slipped 0.3% and the Dow Jones Industrial Average fell 0.9%. European markets were also modestly lower. (AP Photo/Mary Altaffer, File)

Stocks fell on Wall Street Tuesday after the head of a major vaccine maker expressed concern about how effective current jabs will be against the new variant of the coronavirus.

The S&P 500 fell 0.5% as of 10:28 a.m. Eastern. The Dow Jones Industrial Average fell 287 points, or 0.8%, to 34,849 and the Nasdaq was little changed.

Financial companies has some of the biggest losses. Banks fell broadly along with sliding bond yields, which hurts their ability to charge more lucrative interest on loans.

The yield on the 10-year Treasury fell to 1.42% from 1.52% late Monday as investors sought to reduce their exposure to risk. Bank of America fell 1.8% and Discover Financial Services shed 2.9%.

U.S. crude oil prices, which depend on a strong economy, fell 2.8% and weighed down energy stocks. Exxon Mobil fell 1.4%.

The weakness came after Moderna CEO Stephane Bancel told the Financial Times that he expected current vaccines would struggle with the omicron variant. Moderna, along with Pfizer and Johnson & Johnson, make vaccines against COVID-19 that have collectively helped tame the pandemic through 2021 and allowed the global economy to recover. Moderna slumped 5.3%.

That recovery is once again being threatened by a variant of the virus that appears to spread more easily, though much is still unknown about just how much more contagious or dangerous it could be. The economy and markets were hurt by a summer surge of cases from the delta variant, though the impact on the overall recovery wasn't very big.

Markets in Europe and Asia also fell. Many countries have put up barriers to travel in an effort to stem the spread of the omicron variant, which could also hurt global business. The variant is also raising concerns that problems with global supply chains could be made worse if factories and ports shut down.

Investors are also monitoring the latest round of economic data. The Conference Board reported that consumer confidence fell to a nine-month low in November.


The big economic report this week will be Friday's U.S. jobs report from the Labor Department. Wall Street will also get an update Friday on the health of the services sector, which represents the bulk of the economy.

Should you invest $1,000 in Discover Financial Services right now?

Before you consider Discover Financial Services, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Discover Financial Services wasn't on the list.

While Discover Financial Services currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Johnson & Johnson (JNJ)
4.9283 of 5 stars
$146.13-0.5%3.26%9.11Hold$175.86
Discover Financial Services (DFS)
4.9646 of 5 stars
$127.70+1.6%2.19%14.56Hold$126.29
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

Johnson & Johnson's Dip is a Strategic Buy Point for Investors

JNJ shares hit a low, trading near $145 at under 14X earnings. With a high dividend yield, it's poised for a rebound.

Search Headlines: